Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.

Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A. Abstract Text:

BACKGROUND.: Data on the impact of age in acute myeloid leukemia (AML) patients <30 years treated in pediatric and adult trials are scarce. METHODS.: In all, 891 patients <18 years were treated in the pediatric trials AML-BFM 93/98 and 290 adolescents and young adults (>16 to <30 years) in the AMLCG 92/99 and AMLSG HD93/98A trials. Treatment schedules and dose intensities were comparable. RESULTS.: Initial features and risk factors differed considerably between infants (<2 years) and older age groups and only slightly between children (2 to <13), adolescents (13 to <21) and young adults (21 to <30). Treatment results were most favorable in children (5-year event free survival [EFS]: 54% +/- 3%), slightly inferior in adolescents (46% +/- 4%, P = .03), and unfavorable in young adults (28% +/- 5%, P = .0001). Excluding patients with favorable karyotypes, the results were similar in infants and children (EFS: 44% +/- 4% and 46% +/- 3%, respectively) and inferior in adolescents (35% +/- 4%) and young adults (23% +/- 4%). There was an increased, age-related percentage and inferior outcome in patients with >5% bone marrow blasts after induction. EFS was especially poor in young adults, with blasts >5%. The blast count after induction was of no prognostic value in patients with favorable karyotypes, but a significant risk factor in patients with other cytogenetics. CONCLUSIONS.: Biologic data differed mainly between infants and older age groups. When comparing the same age groups, outcome was similar between the trial groups, which differed from reports concerning acute lymphoblastic leukemia. However, the prognosis decreased after childhood independent of other risk factors. This indicates that even in the younger cohorts increasing age may be an additional unfavorable factor. Cancer 2008. (c) 2007 American Cancer Society.

Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Cancer

VOLUME: 112

Page Numbers: 562-71

Journal Abbreviation: Cancer

ISSN: 0008-543X

DAY: 1

MONTH: Feb

YEAR: 2008

Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 374236

Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.

AFFILIATION: Pediatric Hematology/Oncology, Children's Hospital, University of Münster, Münster, Germany.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Cancer

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A Related Publications

• Adenosine and adenosine deaminase.
• Are steroids really the cause for fish feminization? A mini-review of in vitro and in vivo guided TIEs.
• Asking the right question.
• Biomonitoring recycled water in the santa ana river basin in southern california.
• Characterization of Phase I biotransformation enzymes in coho salmon (Oncorhynchus kisutch).
• Characterization of muscle cholinesterases from two demersal flatfish collected near a municipal wastewater outfall in Southern California.
• Determination of codehydrogenase I in tumor tissues.
• Effects of environmental estrogens and antiandrogens on endocrine function, gene regulation, and health in fish.
• Enantioselectivity in estrogenic potential and uptake of bifenthrin.
• Expression and characterization of cytochrome P450 2X1 in channel catfish (Ictalurus punctatus).
• Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia.
• Osmotic regulation of a novel flavin-containing monooxygenase in primary cultured cells from rainbow trout (Oncorhynchus mykiss).
• Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia.
• Recent advanced in the study of tissue metabolism.
• Seasonal evaluation of reproductive status and exposure to environmental estrogens in hornyhead turbot at the municipal wastewater outfall of Orange County, CA.
• Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.
• Studies on the metabolism of ribose; enzymatic conversion of ribose into hexosemonophosphate.
• Synthesis and analysis of optically active triglycerides.
• Synthesis of fenthion sulfoxide and fenoxon sulfoxide enantiomers: effect of sulfur chirality on acetylcholinesterase activity.
• Tetramic and tetronic acids: an update on new derivatives and biological aspects.
• Uptake of estradiol from sediment by hornyhead turbot (Pleuronichthys verticalis) and effects on oxidative DNA damage in male gonads.
• [Not Available.]